Last reviewed · How we verify
NCT05828407: FLUID-REVENGE
Fluid Challenge Impact in the Portal Vein Pulsatility Depending on the Fluid Responsivness Status
trial in Cardiovascular Insufficiency in 36 participants. Completed in 3 June 2024.
3 June 2024
Quick facts
| Lead sponsor | Hospices Civils de Lyon |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 36 |
| Start date | 10 July 2023 |
| Primary completion | 3 June 2024 |
| Estimated completion | 3 June 2024 |
| Sites | 1 location across France |
Conditions studied
- Cardiovascular Insufficiency — all drugs for Cardiovascular Insufficiency →
- Venous Congestion — all drugs for Venous Congestion →
Sponsor
Hospices Civils de Lyon — full company profile →
Who can join
18 and older, any sex, with Cardiovascular Insufficiency or Venous Congestion. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Portal vein pulsatility index is a marker of venous congestion evaluated by point of care ultrasound. It is associated with acute kidney injury, especially in critically ill patients. It may be considered as a dynamic marker. The investigators hypothesized that portal vein pulsatility index is higher after a fluid challenge only in patient without preload dependence in critically ill patients with cardiovascular insufficiency.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
Changes in portal pulsatility index induced by a fluid challenge in patients with haemodynamic instability and systemic venous congestion: a prospective cohort study.
Ruste M, Reskot R, Schweizer R, Mayet V, et al · · 2024 · cited 7× · PMID 39485575 · DOI 10.1186/s13613-024-01391-2 -
Relationship between point-of-care ultrasound venous congestion assessment parameters, intravenous pressure, and venous return: a post-hoc analysis of a prospective cohort study.
Ruste M, Delas Q, Reskot R, Fellahi JL, et al · · 2025 · cited 2× · PMID 40014228 · DOI 10.1186/s13089-025-00421-9
Verify or expand the search:
- PubMed search for NCT05828407
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Hospices Civils de Lyon trials
Trials by the same sponsor.
- NCT07569536 — Efficacy of the Alpha 2 Agonist Dexmedetomidine for Sympathetic Deactivation in REfractory Septic Shock · Phase 3 · not yet recruiting
- NCT07529314 — Evaluating Interventional Radiology for Cancer Pain Management · NA · not yet recruiting
- NCT07273929 — Comparative Study of the Effectiveness of Three Access Routes for Implanting an Electronic Intracardiac Device · Phase 3 · not yet recruiting
- NCT07474532 — Attitudes and Beliefs Related to Benzodiazepine Deprescribing · not yet recruiting
- NCT07313007 — Assessment of Gut Microbiota-Derived Amino Acid Metabolite Production in Patients With MASLD · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05828407 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Hospices Civils de Lyon
- Last refreshed: 7 June 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05828407.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing